ClinicalTrials.gg
RecruitingNCT07890298Updated Oct 22, 2026

A Study to Evaluate the Intracranial Arterial Recanalization With Multiple Doses of LT3001 Drug Product in AIS Participant

A Phase 2 interventional study of LT3001 Drug Product in Acute Ischemic Stroke, sponsored by Lumosa Therapeutics Co., Ltd.. Recruiting at 1 site in Taiwan. Open to participants aged 18 Years to 88 Years. Per ClinicalTrials.gov, last updated 2026-10-22.

Sponsored by Lumosa Therapeutics Co., Ltd. · Phase 2, Interventional, and Basic science

Updated Oct 22, 2026Newly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years to 88 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 64 studies in Ischemic Stroke with a site in Taiwan — 18 open to participants now, 21 under way, 3 of them phase 3. Ischemic Stroke · Taiwan.

Planned enrollment
46th of 52
10 · median 73
Started
2026
with 4 others
Phase 2
9 of 64
2 open now
Primary completion
2027-12
later than 14 of 20 live
Registered
63rd of 64
by date
Lead sponsor
3 of 64
Lumosa Therapeutics Co., Ltd.

Among the 64 studies in Ischemic Stroke with a site in Taiwan, this one is the 46th largest by planned enrollment of the 52 interventional ones that give a count, is one of 5 that started in 2026, is one of 9 in phase 2, reaches primary completion later than 14 of the 20 other live ones, and was the 63rd registered.

Ischemic Stroke

2,619 studies on the registry are indexed under Ischemic Stroke; 978 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

18 of the 64 studies in Ischemic Stroke with a site in Taiwan are open now. Recruiting first, the newest first:

12 more — sign in →

All 18 open studies →

A study can be open while its sites in Taiwan have not opened yet or have stopped. Only those recruiting at a site in Taiwan →

Who these studies take

Of the 662 Ischemic Stroke studies recruiting now, 396 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 26 take children under 18; 42 take healthy volunteers.

This study: 18 Years to 88 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 64 studies in Ischemic Stroke with a site in Taiwan, or all of them as a file.
02

Study summary

This is a phase II, open-label, single-arm, exploratory study to evaluate the intracranial arterial recanalization of multiple doses of LT3001 drug product in participant with acute ischemic stroke (AIS)

Read the detailed description

This is a multicenter, open-labeled, prospective Phase II clinical study, designed to evaluate the effect of the intracranial arterial recanalization in AIS participant receiving LT3001 drug product. The study is planned to take place in multiple sites. Subjects who participate in this trial should be treated with standard of care of AIS therapies when appropriate.

03

Conditions studied

  • Acute Ischemic Stroke

Browse trials for

04

Who can participate

Ages eligible
18 Years to 88 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Participant or participant's legal representative consents to participation by signing the form (ICF) after receiving full information about the study.
  2. Participant is aged 18 to 88 years, inclusive, at the time of Screening (Visit 1).
  3. Participant is not to be treated with intravenous thrombolytic (e.g., recombinant tissue-type plasminogen activator) treatment or endovascular thrombectomy (EVT)
  4. Participant has NIHSS of 6 to 23.
  5. Participant is able to receive the 1st IP within 24 hours after stroke symptoms onset.
  6. Participants who are women of (WOCBP), or men whose sexual partners are WOCBP, are able and willing to use at least 1 highly effective method of during the study until 3 months after last dosing of IP. A female participant is considered to be a WOCBP after menarche and until she is in a state for 12 months or otherwise permanently sterile (for which acceptable methods include hysterectomy, bilateral salpingectomy, and bilateral oophorectomy).

Neuroimaging Inclusion Criteria:

  1. Participant is willing and able to undergo brain computed tomography angiography (CTA) or magnetic resonance angiography (MRA).

    • No known history of severe contrast allergy, anaphylactoid reaction, or other clinical conditions that contraindicate contrast agent administration for CTA or MRA
    • Must not have MRI such as non-MRI-compatible pacemakers, cochlear implants, ferromagnetic implants/devices, claustrophobia, or other conditions preventing safe MRI scanning
  2. Participant is confirmed to have an acute intracranial arterial occlusion.

Exclusion criteria

Exclusion Criteria:

  1. Participant has a pre-stroke disability that requires help for activities of daily living (mRS >2).
  2. Participant has Alberta Stroke Program Early CT Score (ASPECTS) of \<5.
  3. Participant has AOL =3 at Screening (Visit 1).
  4. Participant has symptoms of suspected subarachnoid hemorrhage, even if CT is normal.
  5. Participant has imaging evidence of acute intracranial hemorrhage, intracranial tumor (except small meningioma), arteriovenous malformations, other central nervous system lesions that could increase the risk of bleeding, or aneurysm requiring treatment.
  6. Participant has significant mass effect with midline shift.
  7. Participant has pre-existing medical, neurological, or psychiatric disease that would confound the neurological or functional evaluations, e.g., seizures at onset of the current AIS, dementia.
  8. Participant has current uncontrolled hypertension despite treatment: systolic blood pressure >185 mmHg or diastolic blood pressure >110 mmHg before dosing at Screening (Visit 1).
  9. Participant has hemorrhagic diathesis, coagulation factor deficiency or recent oral anticoagulant therapy with (INR) >1.7 or activated partial thromboplastin time (aPTT) >3 times of at Screening (Visit 1).
  10. Participant has received one of the new oral anticoagulants within 48 hours before the 1st IP administration, e.g., dabigatran, apixaban, rivaroxaban, and edoxaban, except for dabigatran-treated participant who has been given a reversal agent, idarucizumab, before the 1st IP administration.
  11. Participant has count \<100,000/mm3 at Screening (Visit 1).
  12. Participant has blood glucose concentration \<50 mg/dL or >400 mg/dL at Screening (Visit 1).
  13. Participant has moderate or severe hepatic, renal, and/or active infectious disease at Screening (Visit 1) as judged by the investigator. Participant with confirmed COVID-19 or influenza infection can be enrolled at the Investigator's discretion.
  14. Participant is lactating, pregnant (pregnancy test required for all female participants of ), or planning to become pregnant during the study.
  15. Participant has history of sICH, prior AIS, myocardial infarction, serious head trauma, or any major surgery within 90 days before Screening (Visit 1).
  16. Participant has had a bleeding event within 21 days before Screening (Visit 1), e.g., gastrointestinal hemorrhage.
  17. Participant has puncture of noncompressible vessels within 7 days before Screening (Visit 1).
  18. Participant has participated in another study and received investigational product within 30 days before Screening (Visit 1) or 5 half-lives (whichever is longer).
  19. In the opinion of the Investigator, the participant has serious, advanced, or terminal illness that will prevent improvement or follow-up visits.
  20. In the opinion of the Investigator, the participant is not appropriate for the study for any other reason.
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 2
Primary purpose
Basic science
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    LT3001 Drug Product

    Administered by intravenous infusion

    Drug: LT3001 Drug Product

Interventions

06

What researchers measure

Primary outcomes

  1. The rate of successful recanalization at 24 hours after the 1st IP. Successful recanalization is defined as any improvement in Arterial Occlusive Lesion (AOL) score.

    After administer the 1st IP, successful recanalization at 24 hours will be assessed by AOL score and the rate of successful recanalization will be calculated. The Arterial Occlusive Lesion (AOL) score is a 4-point angiographic grading scale (scored 0 to 3) used to measure the degree of recanalization (restoration of blood flow through the blocked target artery) in patients with acute ischemic stroke. Successful recanalization is defined as any improvement in AOL score.

    Time frame: 24 hours

07

Study locations

1 of 1 sites recruiting
  • Taichung Medical University, Taichung
    Taichung, Taiwan
    Recruiting
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Oct 2026; primary completion for Dec 2027, 14 months later.

Of 41 industry-sponsored phase 2 interventional studies under Ischemic Stroke, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 12 and three quarters within 35. This study's planned 14 months is below that.

Counting every sponsor, half of 123 studies reached it within 28 months; a quarter within 15 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 16, 2026
First posted
Oct 22, 2026
StartEst.
Oct 1, 2026
Primary completionEst.
Dec 31, 2027
CompletionEst.
Jun 2028
Last update
Oct 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Registered
First appeared on the registry. No changes since
Oct 22, 2026
Show all 1 update
  1. Oct 22, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT07890298
Lead sponsor
Lumosa Therapeutics Co., Ltd.
Responsible party
Sponsor
First posted
Oct 22, 2026
Start date
Oct 1, 2026 (estimated)
Primary completion
Dec 31, 2027 (estimated)
Completion
Jun 2028 (estimated)
Last update
Oct 22, 2026

Study contacts

Claire Sun
Contact
claire_sun@lumosa.com.tw
+886-2-26557918

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LT3001

Start the discussion